Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and sost in Osteocytes at unloading

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Moriishi, Takeshi ^a   Fukuyama, Ryo ^b   Ito, Masako ^a   Miyazaki, Toshihiro ^a   Maeno, Takafumi ^a,c   Kawai, Yosuke ^a   Komori, Hisato ^a   Komori, Toshihisa ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN BCL 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MASS; CELL DIFFERENTIATION; IN VITRO STUDY; MECHANOTRANSDUCTION; MOUSE; NICK END LABELING; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; PROTEIN EXPRESSION; TRABECULAR BONE; TRANSGENE; UPREGULATION; WILD TYPE;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE RESORPTION; CELL COUNT; CELL DIFFERENTIATION; GLYCOPROTEINS; HINDLIMB SUSPENSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; ORGAN SIZE; OSTEOBLASTS; OSTEOCYTES; OSTEOGENESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSGENES; UP-REGULATION; X-RAY MICROTOMOGRAPHY;

MUS; MUS MUSCULUS;

EID: 84863111789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040143     Document Type: Article

References (58)

1. Wolff J, (1892) Das gesetz der transformation der knochen. Berlin: Springer-Verlag.- Reprint 300 Seiten- Mit vier Nachworten und historischen Dokumenten Auflage 2010.
2. Martin RB, (2000) Does osteocyte formation cause the nonlinear refilling of osteons? Bone 26: 71-78.
3. Ehrlich PJ, Lanyon LE, (2002) Mechanical strain and bone cell function: a review. Osteoporos Int 13: 688-700.
4. Tate MLK, (2003) "Whither flows the fluid in bone?" An osteocyte's perspective. J Biomech 36: 1409-1424.
5. Burger EH, Klein-Nulend J, (1999) Mechanotransduction in bone-role of the lacuno-canalicular network. FASEB Journal 13.
6. Bonewald L, Johnson M, (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42: 606-615.
7. Noble B, (2008) The osteocyte lineage. Arch biochem biophys 473: 106-111.
8. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, et al. (2007) Targeted Ablation of Osteocytes Induces Osteoporosis with Defective Mechanotransduction. Cell Metabolism 5: 464-475.
9. Marotti G, Ferretti M, Remaggi F, Palumbo C, (1995) Quantitative evaluation on osteocyte canalicular density in human secondary osteons. Bone 16: 125-128.
10. Qiu S, Rao DS, Palnitkar S, Parfitt AM, (2002) Relationships between osteocyte density and bone formation rate in human cancellous bone. Bone 31: 709-711.
11. Metz LN, Martin RB, Turner AS, (2003) Histomorphometric analysis of the effects of osteocyte density on osteonal morphology and remodeling. Bone 33: 753-759.
12. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, et al. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO Journal 22: 6267-6276.
13. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, et al. (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. Journal of Experimental Medicine 199: 805-814.
14. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577-4583.
15. Li X, Zhang Y, Kang H, Liu W, Liu P, et al. (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280: 19883-19887.
16. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, et al. (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB Journal 19: 1842-1844.
17. Semenov M, Tamai K, He X, (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280: 26770-26775.
18. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, et al. (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22: 19-28.
19. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, et al. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860-869.
20. Lin C, Jiang X, Dai Z, Guo X, Weng T, et al. (2009) Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24: 1651-1661.
21. Verborgt O, Gibson GJ, Schaffler MB, (2000) Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 15: 60-67.
22. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC, (2007) Perspective: Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 22: 1492-1501.
23. Broker LE, Kruyt FA, Giaccone G, (2005) Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162.
24. Silva MT, Vale A, Santos NMN, (2008) Secondary necrosis in multicellular animals: an outcome of apoptosis with pathogenic implications. Apoptosis 13: 463-482.
25. Schulze C, Munoz L, Franz S, Sarter K, Chaurio R, et al. (2008) Clearance deficiency-A potential link between infections and autoimmunity{star, open}. Autoimmunity Reviews 8: 5-8.
26. Zong WX, (2006) Necrotic death as a cell fate. Genes dev 20: 1-15.
27. Wu Y, Humphrey MB, Nakamura MC, (2008) Osteoclasts- the innate immune cells of the bone. Autoimmunity 41: 183-194.
28. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, et al. (2010) Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol cell biol 30: 3071-3085.
29. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, et al. (2011) Matrix-embedded cells control osteoclast formation. Nat med 17: 1235-1241.
30. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, et al. (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat med 17: 1231-1234.
31. Moriishi T, Maruyama Z, Fukuyama R, Ito M, Toshihiro Miyazaki, et al. (2011) Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis. PLoS ONE 6(11): e27487 doi:10.1371/journal.pone.0027487.
32. Sakai A, Nakamura T, (2001) Changes in trabecular bone turnover and bone marrow cell development in tail-suspended mice. J Musculoskelet Neuronal Interact 1: 387-392.
33. Wang Y, Liu W, Masuyama R, Fukuyama R, Ito M, et al. (2011) Pyruvate dehydrogenase kinase 4 induces bone loss at unloading by promoting osteoclastogenesis. Bone. 50(1): 409-19.
34. Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, et al. (2001) Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 155: 157-166.
35. Yoshida CA, Yamamoto H, Fujita T, Furuichi T, Ito K, et al. (2004) Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev 18: 952-963.
36. Weinstein RS, Nicholas RW, Manolagas SC, (2000) Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. Journal of Clinical Endocrinology and Metabolism 85: 2907-2912.
37. Bonewald LF, (2011) The amazing osteocyte. J Bone Miner Res 26: 229-238.
38. Toyosawa S, Shintani S, Fujiwara T, Ooshima T, Sato A, et al. (2001) Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J Bone Miner Res 16: 2017-2026.
39. Paic F, Igwe JC, Nori R, Kronenberg MS, Franceschetti T, et al. (2009) Identification of differentially expressed genes between osteoblasts and osteocytes. Bone 45: 682-692.
40. Mueller RJ, Richards RG, (2004) Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human, ovine and bovine bone tissues. J Mater Sci Mater Med 15: 367-372.
41. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, et al. (2004) The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol endocrinol 18: 1222-1237.
42. Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I, et al. (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21: 934-945.
43. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, et al. (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283: 5866-5875.
44. Moustafa A, Sugiyama T, Prasad J, Zaman G, Gross TS, et al. (2011) Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int 23: 1225-1234.
45. Heino TJ, Hentunen TA, Vaananen HK, (2002) Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: enhancement by estrogen. J Cell Biochem 85: 185-197.
46. You L, Temiyasathit S, Lee P, Kim CH, Tummala P, et al. (2008) Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone 42: 172-179.
47. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, et al. (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17: 1235-1241.
48. Lazenby RA, (1990) Continuing periosteal apposition. II: The significance of peak bone mass, strain equilibrium, and age-related activity differentials for mechanical compensation in human tubular bones. Am J Phys Anthropol 82: 473-484.
49. Martin RB, Burr DB, Sharkey NA, (1998) Skeletal Tissue Mechanics. Springer. 392 p.
50. Russo C, Lauretani F, Seeman E, Bartali B, Bandinelli S, et al. (2006) Structural adaptations to bone loss in aging men and women. Bone 38: 112-118.
51. Seeman E, (2001) During aging, men lose less bone than women because they gain more periosteal bone, not because they resorb less endosteal bone. Calcif Tissue Int 69: 205-208.
52. Hedgecock N, Hadi T, Chen A, Curtiss S, Martin R, et al. (2007) Quantitative regional associations between remodeling, modeling, and osteocyte apoptosis and density in rabbit tibial midshafts. Bone 40: 627-637.
53. Zhao W, Byrne MH, Wang Y, Krane SM, (2000) Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen. J Clin Invest 106: 941-949.
54. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, et al. (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19: 1842-1844.
55. Li X, (2005) Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling. J Biol Chem 280: 19883-19887.
56. Semenov M, (2005) SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor. J Biol Chem 280: 26770-26775.
57. Li X, Ominsky MS, Niu Q-T, Sun N, Daugherty B, et al. (2008) Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength. J Bone Miner Res 23: 860-869.
58. Schwab P, Klein RF, (2008) Nonpharmacological approaches to improve bone health and reduce osteoporosis. Curr Opin Rheumatol 20: 213-217.